Akademisyen
DÜZGÜN ÖZATLI
PROFESÖR
ONDOKUZ MAYIS ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 51
- Proje 0
- Kitap 3
- Bildiri 20
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
9
Q2
15
Q3
21
Q4
6
WoS (JCR)
Q1
5
Q2
3
Q3
21
Q4
21
TR Index
11
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
3
Ort. yüzdelik
52.5%
Üst %1 payı
0.0%
Üst %10 payı
6.2%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2026 Real-world data on the use of asciminib in chronic-phase chronic myeloid leukemia after two or more prior tyrosine kinase inhibitors: Results of the Turkish managed access program along with a literature review YÖKSİS SJR Q2 JCR Q2 OpenAlex 42.8%
- 2026 Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia YÖKSİS SJR Q3 JCR Q4 OpenAlex 46.9%
- 2025 Clinical Manifestations, Treatment Characteristics and Clinical Outcome in Patients with Acquired Thrombotic Thrombocytopenic Purpura (aTTP) in the Real-World Setting: An Interim Analysis of the Turkish aTTP Registry YÖKSİS TR Index SJR Q3 JCR Q3 OpenAlex 12.0%
- 2024 Real-Life Use of Asciminib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Results of the Turkish Managed Access Program YÖKSİS SJR Q1 JCR Q1
- 2023 International Forum The Turkish perspective on apheresis activity: The Turkish apheresis registry report YÖKSİS SJR Q3 JCR Q4 OpenAlex 43.1%
- 2023 Share Real-world data on the effectiveness and safety of Ixazomib-Lenalidomide-Dexamethasone therapy in relapsed/refractory multiple myeloma patients: a multicenter experience in Turkey. YÖKSİS SJR Q3 JCR Q3 OpenAlex 70.0%
- 2022 The Real\u2010World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL YÖKSİS SJR Q2 JCR Q3 OpenAlex 67.2%
- 2022 Efficacy of preoperative therapeutic plasma exchange in patients with hyperthyroidism and factors affecting the number of sessions YÖKSİS SJR Q2 JCR Q3 OpenAlex 63.1%
- 2022 Oscillometric evaluation of the effects of cardiotoxic chemotherapeutic agents on vascular stiffness YÖKSİS SJR Q2 JCR Q4 OpenAlex 5.1%
- 2021 An Experience on Pomalidomide in Patients within Relapsed/Refractory Multiple Myeloma - A Multicenter Study in Turkey YÖKSİS OpenAlex 0.8%
- 2021 Apheresis in patients with sepsis: A multicenter retrospective study YÖKSİS SJR Q3 JCR Q4 OpenAlex 75.7%
- 2019 The Turkish experience with therapeutic plasma exchange: A national survey YÖKSİS SJR Q3 JCR Q4 OpenAlex 59.5%
- 2019 A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience YÖKSİS TR Index SJR Q3 JCR Q4 OpenAlex 78.2%
- 2018 Impact of Fluorescent In Situ Hybridization Aberrations and CLLU1 Expression on the Prognosis of Chronic Lymphocytic Leukemia: Presentation of 156 Patients from Turkey YÖKSİS TR Index SJR Q4 JCR Q4 OpenAlex 52.5%
- 2014 The Relationship of T Helper 2 Pathway Components Interleukin 4 Interleukin 10 Immunoglobulin E and Eosinophils with Prognostic Markers in Non Hodgkin Lymphoma A Case Control Study YÖKSİS TR Index SJR Q4 JCR Q4 OpenAlex 59.2%
- 2014 Predicting survival for multiple myeloma patients using baseline neutrophil lymphocyte ratio YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 91.1%
- 2013 In Vitro Effect of Ankaferd Blood Stopper®, a Plant Extract Against Mycobacterium tuberculosis Isolates YÖKSİS TR Index SJR Q3 JCR Q4 OpenAlex 70.5%
- 2013 Prognostic impact of LIM domain only 2 LMO2 in chronic myelogenous leukaemia YÖKSİS SJR Q1 JCR Q1 OpenAlex 4.9%
- 2013 Kronik Miyeloproliferatif Hastalıklarda JAK2V617F Mutasyonu YÖKSİS OpenAlex 17.5%
- 2012 Hematolojik hastalıklarda splenektomi tek merkez deneyimi YÖKSİS SJR Q4 OpenAlex 50.3%